Data_Sheet_2_Effect of different interventions on the treatment of high-risk human papillomavirus infection: a systematic review and network meta-analysis.PDF

BackgroundPersistent infection with high-risk human papillomavirus (HR-HPV) can lead to cervical intraepithelial neoplasia and cancer. At present, there is no medication that specifically targets HR-HPV infection.ObjectiveThis study aimed to evaluate the effectiveness of different interventions in promoting HR-HPV regression using a MeSH meta-analysis method.MethodsA search for randomized controlled trials (RCTs) reporting different interventions for the treatment of HR-HPV infection included PubMed, Web of Science, Embase and Cochrane Library from the inception of the databases to March 8, 2023. Two researchers independently screened the articles, extracted data, and evaluated the quality. The literature that met the inclusion criteria was selected, the quality and risk of bias of the included studies were assessed according to the Cochrane 5.1 manual, and NMA was performed using Stata 16.0. The area under the cumulative ranking probability graph (SUCRA) represented the probability that each treatment would be the best intervention.ResultsNine studies involving 961 patients and 7 treatment options were included in the analysis. The results of the network meta-analysis indicated the following rank order in terms of promoting HR-HPV conversion: Anti-HPV biological dressing > vaginal gel > imiquimod > REBACIN® > interferon > probiotics > observation/placebo > Polyphenon E.ConclusionAnti-HPV biological dressing treatment was found to be significantly effective in promoting HR-HPV conversion. However, further validation of the findings is necessary due to the limited number and quality of studies included in the analysis.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42023413917.

背景：高危人乳头瘤病毒（HR-HPV）的持续感染可能导致宫颈上皮内瘤变及癌症。目前尚无针对HR-HPV感染的特异性药物。研究目的：本研究旨在通过MeSH元分析的方法评估不同干预措施在促进HR-HPV消退方面的有效性。研究方法：检索了PubMed、Web of Science、Embase和Cochrane Library数据库中报道不同干预措施治疗HR-HPV感染的随机对照试验（RCTs），检索时间范围从数据库建立至2023年3月8日。两位研究人员独立筛选文献、提取数据并评估质量。符合纳入标准的文献被选中，纳入研究的质量及偏倚风险根据Cochrane 5.1手册进行评估，并使用Stata 16.0进行网络Meta分析。累积排名概率图（SUCRA）下的面积代表了每种治疗方案成为最佳干预措施的概率。结果：共纳入9项研究，涉及961名患者和7种治疗方案。网络Meta分析结果表明，在促进HR-HPV转化的排名顺序为：抗HPV生物敷料 > 阴道凝胶 > 艾美曲普坦 > REBACIN® > 干扰素 > 益生菌 > 观察安慰剂 > 多酚酮。结论：研究发现，抗HPV生物敷料治疗在促进HR-HPV转化方面具有显著疗效。然而，由于分析中纳入的研究数量和质量有限，因此需要对研究结果进行进一步验证。系统综述注册：https://www.crd.york.ac.uk/prospero/，标识符CRD42023413917。